AcuraStem utilizes its proprietary iNeuroRx® technology platform to create individual patient models that accurately replicate neurodegenerative disease processes, enabling the discovery of effective treatments for conditions like sporadic ALS and frontotemporal dementia (FTD). This patient-based approach addresses the limitations of traditional animal models, leading to therapies that can benefit a broader range of patients beyond genetically defined subtypes.
Funding
$4.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional drug development for neurodegenerative diseases relies heavily on animal models, which often fail to accurately replicate the complexities of human disease, leading to ineffective treatments in clinical trials. This approach limits the understanding of the actual mechanisms driving neurodegeneration in patients, especially for sporadic cases of diseases like ALS and FTD.
Solution
AcuraStem employs its iNeuroRx® technology platform to create patient-specific models that mimic neurodegenerative disease processes, enabling the discovery of more effective and broadly applicable therapeutics. By using patient-derived cells, AcuraStem overcomes the limitations of animal models, leading to treatments that address the underlying causes of disease in a wider range of patients, including those with sporadic forms of ALS and FTD. This patient-based approach facilitates the identification of novel drug targets and the development of personalized therapies tailored to individual patient profiles.
Target Audience
AcuraStem's primary target audience includes pharmaceutical companies and research institutions focused on developing treatments for neurodegenerative diseases, particularly ALS and FTD.
Features
- iNeuroRx® platform: Creates patient-specific disease models using patient-derived cells.
- Disease modeling: Accurately replicates neurodegenerative disease processes in vitro.
- Target identification: Facilitates the discovery of novel drug targets relevant to human disease.
- Personalized therapies: Enables the development of treatments tailored to individual patient profiles.